RESUMEN
Intravesical therapy is the gold standard in the treatment of nonmuscle invasive bladder cancer (NMIBC). Despite the efficacy of intravesical therapies, the best treatment options are not determined yet. Development in research of bladder cancer shows several new intravesical drugs and its delivery systems. Additionally, the novel knowledge of bladder cancer immune reaction improves and provides ambitious treatment strategies. The future of NMIBC therapy will be changed by the development of immunotherapy and new technologies for device-assisted treatment. This review focuses on recent advances in the intravesical therapy of NMIBC, viral gene therapy, new technology of intravesical chemotherapy, and drug delivery system.
RESUMEN
The heterogeneity of cancer makes it difficult to predict the prognosis of treatment. There is still a lack of preclinical model systems that reflect the clinical characteristics of patients who have heterogenetic tumors. Advances in 3-dimentional (3D) cell culture are leading to discoveries that occur in the development and progression of cancer that has not been known. There are many models including patient-derived xenograft, patient-derived organoid and spheroid, patient-derived explant, scaffold-based model, and system-based model. Each 3D model has its strengths and limitations. One model cannot answer every question, so it seems most reasonable to approach multiple models when studying cancer heterogeneity. Hopefully, 3D tumor modeling will make tremendous progress on this path by fusion of innovative biomaterials and advanced modeling techniques that can partially mimic the heterogeneous environment of real tumors.
RESUMEN
Background@#This study aimed to assess the potential efficacy of purified porcine atelocollagen (PAC) for the management of refractory chronic pain due to suspected connective tissue damage. @*Methods@#Patients treated with PAC were retrospectively evaluated. Patients with chronic refractory pain, suspected to have originated from musculoskeletal damage or defects with the evidence of imaging studies were included. Pain intensity, using the 11-point numerical rating scale (NRS), was assessed before the procedure, and 1 month after the last procedure. @*Results@#Eighty-eight patients were finally included for investigation. The mean NRS score was decreased from 5.8 to 4.1 after 1 month of PAC injection (P < 0.001). No independent factor was reported to be directly related to the decrease in NRS score by more than half. @*Conclusions@#Application of PAC may have potential as a treatment option for refractory chronic musculoskeletal pain. PAC might promote tissue recovery, act as a scaffold for repair, or directly reduce inflammation.